UPDATE: Piper Jaffray Upgrades Intra-Cellular Therapies (ITCI) to Overweight; Trial Shows Luma' Differentiated
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Wall St indexes split, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Intra-Cellular Therapies (ITCI) PT Raised to $22 at SunTrust Robinson Humphrey
September 7, 2017 12:52 PM EDTSunTrust Robinson Humphrey raised its price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $22.00 (from $16.00) while maintaining a Hold rating.
Analyst Edward Nash said efficacy findings are "encouraging" and could provide additional support for FDA approval.
... MoreIntra-Cellular Therapies (ITCI) Reports Positive Topline Data From 6-Week Open-label Safety Switching Study with Lumateperone
September 7, 2017 7:13 AM EDTIntra-Cellular Therapies, Inc. (NASDAQ: ITCI) today announced positive topline data from the first part of an open-label safety switching study in which 302 patients with stable symptoms of schizophrenia were switched from standard-of-care antipsychotic medications to lumateperone (ITI-007 60 mg) with no dose titration of lumateperone required for a 6-week treatment duration, then switched back to standard-of-care. Many currently available antipsychotic agents are associated with motor side effects and/or weight gain, cardiovascular liabilities, dyslipidemia, and hyperglycemia. In this study, lumateperone was generally well tolerated with a favorable safety profile. Statistically significant improvements from standard-of-care baseline were... More
